The AmoyDx EML4-ALK Fusion Gene Detection Kit is a sensitive and selective assay for the detection of the twenty-one most common fusion transcripts of the chimeric EML4-ALK gene.
The EML4-ALK fusion oncogene represents one of the newest molecular targets in non-small-cell lung cancer (NSCLC). First described in 2007, the fusion results from a small inversion within chromosome 2p. This inversion leads to expression of a chimeric tyrosine kinase having the N-terminal half of echinoderm microtubule-associated protein-like 4 (EML4) fused to the intracellular kinase domain of anaplastic lymphoma kinase (ALK). The EML4-ALK protein possesses potent oncogenic activity both in vitro and in vivo. This activity can be blocked by small-molecule inhibitors, supporting a role for EML4-ALK as a key driver of lung tumorigenesis.